论文部分内容阅读
目的探讨莫西沙星联合无创正压通气治疗慢性阻塞性肺疾病(COPD)的临床效果。方法将80例COPD患者随机分为观察组和对照组,每组40例,对照组采用莫西沙星治疗,观察组采用莫西沙星联合无创正压通气治疗,比较2组临床症状消失时间、临床疗效和肺功能变化情况。结果观察组咳嗽、肺部哮鸣音消失时间短于对照组,总有效率为100.00%高于对照组的80.00%,最大呼气流速、1s用力呼气容积和最大呼气中段流量均高于对照组,差异有统计学意义(P<0.01)。结论采用莫西沙星联合无创正压通气治疗COPD临床效果较好。
Objective To investigate the clinical effect of moxifloxacin combined with non-invasive positive pressure ventilation in the treatment of chronic obstructive pulmonary disease (COPD). Methods Eighty patients with COPD were randomly divided into observation group and control group, 40 cases in each group. The control group was treated with moxifloxacin. The observation group was treated with moxifloxacin combined with noninvasive positive pressure ventilation. The disappearance time of clinical symptoms, Efficacy and changes in lung function. Results The observation group cough, lung wheeze disappeared less than the control group, the total effective rate was 100.00% higher than 80.00% of the control group, the maximum expiratory flow, forced expiratory volume 1s and maximum expiratory flow were higher than the middle The control group, the difference was statistically significant (P <0.01). Conclusion Moxifloxacin combined with non-invasive positive pressure ventilation in the treatment of COPD is better.